Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by World Investment Advisors

World Investment Advisors grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,564 shares of the medical research company's stock after purchasing an additional 4,016 shares during the quarter. World Investment Advisors' holdings in Edwards Lifesciences were worth $5,259,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth $26,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences in the 4th quarter worth $27,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $29,000. Global X Japan Co. Ltd. increased its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC increased its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the transaction, the vice president owned 47,206 shares in the company, valued at $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at $15,565,087. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,648 shares of company stock valued at $2,998,866. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 0.3%

NYSE EW traded down $0.25 during trading hours on Friday, reaching $76.77. The company had a trading volume of 1,679,364 shares, compared to its average volume of 5,253,911. The stock has a 50-day moving average of $76.12 and a 200 day moving average of $73.28. Edwards Lifesciences Corporation has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $45.03 billion, a P/E ratio of 10.97, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on EW shares. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Piper Sandler upped their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Citigroup reaffirmed a "buy" rating and set a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.